• News
  • SAN DIEGO
  • BioTech

Sorrento earns SBIR grant

Sorrento Therapeutics Inc. (Nasdaq: SRNE) received funding from the National Institutes of Health to advance an immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of idiopathic pulmonary fibrosis, which affects more than 100,000 Americans.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!